BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One 2013;8:e61538. [PMID: 23620762 DOI: 10.1371/journal.pone.0061538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 La Rosa S. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future. Endocr Pathol 2023;34:79-97. [PMID: 36797453 DOI: 10.1007/s12022-023-09755-3] [Reference Citation Analysis]
2 Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K, Welin S, Tiensuu Janson E. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocr Relat Cancer 2023;30. [PMID: 36629395 DOI: 10.1530/ERC-22-0316] [Reference Citation Analysis]
3 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Zagainov VE, Belskii VA, Korneva KG, Kuchin DM, Baranova AA. A rare case report of surgical treatment of pancreatic VIPoma. Ann hir gepatol 2020;25:113-118. [DOI: 10.16931/1995-5464.20201113-118] [Reference Citation Analysis]
5 Bates DDB, de Paula MCF, Horvat N, Sheedy S, Lall C, Kassam Z, Pickhardt P, Lalwani N, Ganeshan D, Petkovska I. Beyond adenocarcinoma: MRI of uncommon rectal neoplasms and mimickers. Abdom Radiol (NY) 2019;44:3581-94. [PMID: 31069482 DOI: 10.1007/s00261-019-02045-9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hendifar AE, Ramirez RA, Anthony LB, Liu E. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas 2019;48:1111-8. [PMID: 31609931 DOI: 10.1097/MPA.0000000000001391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Lim KHJ, Valle JW, Lamarca A. Unusual skull base metastasis from neuroendocrine tumor: a case report. J Med Case Rep 2019;13:273. [PMID: 31466520 DOI: 10.1186/s13256-019-2214-5] [Reference Citation Analysis]
8 Sakin A, Tambas M, Secmeler S, Can O, Arici S, Yasar N, Geredeli C, Demir C, Cihan S. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pac J Cancer Prev 2018;19:3597-603. [PMID: 30583688 DOI: 10.31557/APJCP.2018.19.12.3597] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. Endocr Connect 2018;7:1535-41. [PMID: 30530877 DOI: 10.1530/EC-18-0478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Alshaikh OM, Asa SL, Mete O, Greig PD, Mcgilvray I, Ezzat S. Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. AACE Clinical Case Reports 2018;4:e289-e293. [DOI: 10.4158/accr-2017-0128] [Reference Citation Analysis]
11 Bu J, Youn S, Kwon W, Jang KT, Han S, Han S, You Y, Heo JS, Choi SH, Choi DW. Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification. Ann Hepatobiliary Pancreat Surg 2018;22:66-74. [PMID: 29536058 DOI: 10.14701/ahbps.2018.22.1.66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
12 A. Boos L, Komminoth P. Tumor Staging TNM. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_4] [Reference Citation Analysis]
13 Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018;472:341-9. [PMID: 29134440 DOI: 10.1007/s00428-017-2258-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 13.8] [Reference Citation Analysis]
14 Clift AK, Faiz O, Goldin R, Martin J, Wasan H, Liedke MO, Schloericke E, Malczewska A, Rindi G, Kidd M, Modlin IM, Frilling A. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocr Connect 2017;6:71-81. [PMID: 28104724 DOI: 10.1530/EC-16-0114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
15 Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 2016;3:203-19. [PMID: 30338051 DOI: 10.2217/ije-2016-0006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
16 Bellorin O, Shuchleib A, Halevi AE, Aksenov S, Saldinger PF. Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report. Int J Surg Case Rep 2016;25:62-5. [PMID: 27327559 DOI: 10.1016/j.ijscr.2016.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J Nucl Med. 2016;57:34-40. [PMID: 26471695 DOI: 10.2967/jnumed.115.166017] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 11.3] [Reference Citation Analysis]
18 Ye BX, Heng D, Jiang LQ, Wang Y, Zhang HJ, Lin L. Application of AJCC/UICC and WHO-2010 classifications for GEP-NEN in Chinese patients. J Dig Dis 2015;16:264-71. [PMID: 25707298 DOI: 10.1111/1751-2980.12239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Gleason D, Miller-hammond KE, Gibbs JF. Small Bowel Cancer. In: Chu QD, Gibbs JF, Zibari GB, editors. Surgical Oncology. New York: Springer; 2015. pp. 217-34. [DOI: 10.1007/978-1-4939-1423-4_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Pasieka JL, Dixon E. Small bowel neuroendocrine tumors: the benefits of surgical intervention. International Journal of Endocrine Oncology 2014;1:87-96. [DOI: 10.2217/ije.14.5] [Reference Citation Analysis]
21 Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, Liu X, Zhang L, Giordano TJ, Bellizzi AM, Chen JH, Shi C, Allen P, Reidy DL, Wolfgang CL, Saka B, Rezaee N, Deshpande V, Klimstra DS. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437-447. [PMID: 24503751 DOI: 10.1097/pas.0000000000000169] [Cited by in Crossref: 167] [Cited by in F6Publishing: 180] [Article Influence: 18.6] [Reference Citation Analysis]
22 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]